Upcoming Allied Market Research
Kearns-sayre Syndrome Market

Kearns-Sayre Syndrome Market

Size, Share, Competitive Landscape and Trend Analysis Report by Test Type (Genetic Test, Muscle Biopsy, Biochemical Test), by Drug Type (CoQ10, L-carnitine, Creatine), by Treatment Type (Vitamins, Anti-oxidants, Supportive Targeted Therapy), by Route of Administration (Oral, Injection, Intravenous) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A14006
Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.


Kearns-Sayre syndrome (KSS) is a rare multisystemic disorder, which is a condition that affects many parts of the body, especially the eyes. Kearns-Sayre syndrome belongs to a group of rare disorders known as mitochondrial myopathies. Mitochondrial myopathies are a group of neuromuscular disorders that are caused by mitochondrial dysfunction. Mitochondria is commonly known as the powerhouse of the cell, which is a small energy-producing structure. The nerve cells which reside in the brain require a lot of energy and hence they appear to be damaged when mitochondrial dysfunction occurs. Kearns-Sayre syndrome symptoms usually occur before the age of 20, and the disorder is identified by a few characteristic signs and symptoms. Moreover, external ophthalmoplegia (weakness or paralysis of the eye muscles) impairs eye movement and causes drooping eyelids (ptosis) in people with Kearns-Sayre syndrome. The symptoms observed are blindness, weakness in muscle cells, heart failure, vomiting, deafness, and seizures. The prognosis of the disorders in severity ranges from progressive weakness to death.

COVID-19 Impact Analysis

  • COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
  • Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global Kearns-Sayre syndrome market. 

Top Impacting Factors
Increasing number of cases of mitochondrial myopathies across the globe helps to boost the growth of market. Rising number of screening for genetic diseases, increasing geriatric population, ongoing clinical trials uplift the market growth.
In addition, rise in investment by R&D in pharmaceutical companies and increase in the availability of healthcare policies are some of the crucial factors driving the Kearns-Sayre syndrome market growth.
Furthermore, rise in research and development activities to develop novel therapies, increase in healthcare expenditure, and improving healthcare infrastructure positively impact the market growth.
However, poor number of treatment options due to rare nature of the disease and unavailability of curative treatment restrain the growth of the market.
Market Trends
New Product Launches to Flourish the Market

  • In October 2019, Alexion Pharmaceuticals, Inc. and Stealth BioTherapeutics Corp. announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. It is evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM)—a genetic mitochondrial disease. The elamipretide is a novel, potential therapy that targets mitochondrial dysfunction.
  • In January 2020, NeuroVive Pharmaceutical AB recruited a few healthy candidates for the second installment of Phase 1a/b study, focused on testing KL1333, its oral treatment candidate for mitochondrial diseases. The study is performed to develop an investigational molecule that could help treat various genetic mitochondrial diseases, such as mitochondrial encephalomyopathy and Kearns-Sayre syndrome.

Key Benefits of the Report

  • This study presents the analytical depiction of the Kearns-Sayre syndrome market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Kearns-Sayre Syndrome Market Report

  • Which are the leading market players active in the Kearns-Sayre syndrome market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is Kearns-Sayre syndrome market?
  • What is Kearns-Sayre syndrome market prediction in the future?
  • Who are the leading global players in the Kearns-Sayre syndrome market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the Kearns-Sayre syndrome market report?

Kearns-Sayre Syndrome Market Report Highlights

Aspects Details
By Test Type
  • Genetic Test
  • Muscle Biopsy
  • Biochemical Test
By Drug Type
  • CoQ10
  • L-carnitine
  • Creatine
By Treatment Type
  • Vitamins
  • Anti-oxidants
  • Supportive & Targeted Therapy
By Route of Administration
  • Oral
  • Injection
  • Intravenous
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players GeneDx Inc, Abliva AB., Stealth Bio Therapeutics Inc., CENTOGENE N.V., Reata Pharmaceuticals Inc., AbbVie Inc, Gino Cortopassi, Khondrion BV, Mitobridge Inc.

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Purchase Options

Call or Email Us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Kearns-sayre Syndrome Market

Start reading.
This Report and over 71,230+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,870
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Related Reports

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of the scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time for readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of the scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save the time of readers